Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
282.88
+0.49 (0.17%)
Apr 25, 2025, 12:35 PM EDT - Market open
Cencora Revenue
Cencora had revenue of $81.49B in the quarter ending December 31, 2024, with 12.78% growth. This brings the company's revenue in the last twelve months to $303.19B, up 11.64% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$303.19B
Revenue Growth
+11.64%
P/S Ratio
0.18
Revenue / Employee
$6,591,148
Employees
46,000
Market Cap
54.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
COR News
- 20 days ago - 3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock - Barrons
- 25 days ago - These 15 stocks are the most profitable companies in the S&P 500 - Market Watch
- 4 weeks ago - Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release - Business Wire
- 2 months ago - Cencora: Higher Potential Returns After Reduced Walgreens Stake - Seeking Alpha
- 2 months ago - Cencora Announces Common Share Repurchase From Walgreens Boots Alliance - Business Wire
- 2 months ago - Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds - Business Wire
- 2 months ago - Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program - Business Wire
- 2 months ago - Cencora (COR) Q1 2025 Earnings Call Transcript - Seeking Alpha